Title : Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.

Pub. Date : 2021 Sep

PMID : 34243078






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSIONS: This is the largest prospective study in advanced BRAF V600-mutant melanoma patients treated with D + T, conducted in conditions close to "real-world practice". Thymidine B-Raf proto-oncogene, serine/threonine kinase Homo sapiens